- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04720469
A Second Magnetic Resonance Guided Focused Ultrasound Thalamotomy for Essential Tremor
A Safety Pilot Clinical Trial of a Second Magnetic Resonance Guided Focused Ultrasound (MRgFUS) Thalamotomy for the Management of Medication-refractory Essential Tremor
This study will be a single-centre, prospective, single-arm, open-label, 12-week pilot trial assessing the safety and preliminary efficacy of a second MR-guided focused ultrasound (MRgFUS) thalamotomy on the naïve brain hemisphere after 48 weeks or more of the first MRgFUS thalamotomy in patients with medication-refractory ET.
This study will be conducted at the Focused Ultrasound Centre of Excellence at Sunnybrook Health Sciences Centre/University of Toronto.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Individuals aged 22 years or older;
- Subjects who are able and willing to give consent and able to attend all study visits and MRgFUS procedure, understanding the associated risks, benefits, and alternative treatments;
- Diagnosis of ET as confirmed from clinical history and examination by a neurologist or neurosurgeon and unilateral MRgFUS thalamotomy at least 48 weeks prior;
- On a stable dose of medication for tremor for at least 4 weeks;
- Medication-refractory criterion: tremor refractory to adequate trials of at least two medications, one of which should be a first line therapy of either propranolol or primidone. An adequate medication trial is defined as a therapeutic dose of each medication or the development of side effects as the medication dose is titrated;
- Moderate-severe tremor severity criteria in the untreated hand: Despite medical treatment, untreated hand score of ≥2 points in the postural or intention component of the item 5 or 6 in the Part A of CRST, AND untreated hand score of ≥2 points in any one of the items 12-15 of the Part B of CRST;
- Disability criterion: ≥2 points in any one of the Part C items 17-23 as measured by the CRST;
- Able to communicate sensations during the MRgFUS treatment and to press the device STOP button.
Exclusion Criteria:
- Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc;
- Women who are pregnant;
- Gait subscore ≥2 points in the SARA scale;
- Speech subscore ≥2 points in the SARA scale;
- Patients with advanced kidney disease (with estimated glomerular filtration rate <30 mL/min/1.73m2) or on dialysis;
Patients with unstable cardiac status or severe hypertension including:
- Documented myocardial infarction within six months of enrollment
- Unstable angina on medication
- Unstable or worsening congestive heart failure
- Left ventricular ejection fraction below the lower limit of normal
- History of a hemodynamically unstable cardiac arrhythmia
- Cardiac pacemaker
- Severe hypertension (diastolic BP > 100 on medication);
- Patients exhibiting any behaviour(s) or clinical assessment consistent with ethanol or substance abuse;
- Patients with history of abnormal bleeding, hemorrhage, and/or coagulopathy defined as abnormal coagulation profile (platelet < 100,00/μl), PT (>14 sec) or PTT (>36 sec), and INR > 1.3;
- Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g. Avastin) within one month of focused ultrasound procedure;
- Ischemic or hemorrhagic stroke within 6 months;
- Patients with brain tumors;
- Individuals who are not able or unwilling to tolerate the required prolonged stationary position during treatment (approximately 2-3 hours);
- Patients who are currently participating in another clinical investigation with an active treatment arm;
- Patients who have had deep brain stimulation (DBS) or a prior stereotactic ablation of the basal ganglia with GKRS or radiofrequency;
- Patients who have been administered botulinum toxins into the arm for 5 months prior to baseline.
- Evidence of clinically important movement disorder, such as chorea, dystonia, or parkinsonism. Anyone with the presence of parkinsonian features including bradykinesia, rigidity, or postural instability will be excluded. Subjects who exhibit only mild resting tremor but no other symptoms or signs of Parkinson's disease may be included.
- Symptoms and signs of increased intracranial pressure (e.g. headache, nausea, vomiting, lethargy, and papilledema);
- Untreated, uncontrolled sleep apnea;
- Presence of any other neurodegenerative disease like multisystem atrophy, progressive supranuclear palsy, dementia with Lewy bodies, and Alzheimer's disease;
- Mild cognitive impairment with impairment in the domain of language as determined by screening neuropsychological battery and judged by study neuropsychologist;
- A known diagnosis of dementia of any cause;
- Uncontrolled major psychiatric disorder or suicidal ideation. Patients with psychiatric disorders identified on initial screening can be treated for these conditions before MRgFUS treatment and enrolled if deemed psychiatrically stable for at least three months before study entry. Any presence of psychosis will be excluded;
- Any illness that in the investigator's opinion preclude participation in this study;
- Patients with a history of seizures within the past year.
- Inability to generate a thermal thalamic lesion during the first MRgFUS procedure;
- Poor tolerance to the first MRgFUS procedure;
- Severe adverse event or moderate-severe adverse event related to the MRgFUS procedure or thalamotomy, such as clinically significant and permanent speech, language, sensory, motor or gait dysfunction.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with bilateral essential tremor who have undergone one MRgFUS thalamotomy
|
Ablation of untreated thalamus using focused ultrasound to abate tremor.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence at week 12 of new onset or significant worsening of: ataxic gait; speech impairment; cognitive impairment; contralateral weakness; patient-reported disabling sensory loss; Severe AEs related to the MRgFUS procedure.
Time Frame: 12 weeks
|
This composite outcome will be measured by the Scale for the Assessment and Rating of Ataxia (SARA) scale, neuropsychology battery, neurological examination and AE reports.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the tremor score (Part A and B) from baseline to 12 weeks after MRgFUS thalamotomy, adjusted for baseline scores.
Time Frame: 12 weeks
|
This CRST subscore will be measured on the treated side.
|
12 weeks
|
Change in QUEST global score and EQ-5D from baseline to 12 weeks after MRgFUS, adjusted for baseline scores.
Time Frame: 12 weeks
|
QUEST (Quality of Life in Essential Tremor) is a disease-specific quality of life scale.
|
12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in speech intelligibility and speaking rate from baseline to 12 weeks after MRgFUS thalamotomy, adjusted for baseline scores.
Time Frame: 12 weeks
|
Speech intelligibility is measured as the percentage of intelligible words and speaking rate is measured as words per minute.
|
12 weeks
|
Change in the subscores of neuropsychological tests and self-reported questionnaires from baseline to 12 weeks after MRgFUS thalamotomy.
Time Frame: 12 weeks
|
Alternative versions of the neuropsychological tests and self-reported questionnaires of cognitive function will be used in the baseline and week 12 visit to account for a learning effect.
|
12 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Agessandro Abrahao, MD, MSc, Sunnybrook Health Sciences Centre
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3341
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Essential Tremor
-
Emory UniversityCompletedEssential Tremor | Essential Vocal Tremor | Essential Voice Tremor | Voice Tremor | Vocal TremorUnited States
-
Syracuse UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedEssential Voice Tremor | Voice Tremor | Vocal Tremor | Essential Tremor of VoiceUnited States
-
ES Therapeutics Australia Pty LtdRecruitingTremor, EssentialCanada
-
InSightecActive, not recruitingNeurologic Manifestations | Tremor | Tremor, EssentialKorea, Republic of, Canada
-
University of MinnesotaRecruitingEssential Tremor | Upper Extremity Essential TremorUnited States
-
SK Life Science, Inc.CompletedEssential Tremor, Movement Disorders
-
Xiangya Hospital of Central South UniversityEnrolling by invitation
-
Merz Pharmaceuticals GmbHCompletedEssential Tremor of the Upper LimbUnited States, Canada, Poland
-
Merz Pharmaceuticals GmbHCompleted
-
University Hospital, Clermont-FerrandAllerganCompletedEssential Head TremorFrance
Clinical Trials on MRgFUS thalamotomy
-
Chinese PLA General HospitalRecruitingMovement DisordersChina
-
InSightecTerminatedEssential TremorChina, Japan, Taiwan
-
Chinese PLA General HospitalRecruitingNeuropathic Pain | Magnetic Resonance ImagingChina
-
InSightecCompletedParkinson's DiseaseUnited States
-
InSightecActive, not recruitingTrigeminal Neuropathic PainUnited States
-
InSightecUnknown
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Unknown
-
Université de SherbrookeUniversity Health Network, TorontoRecruiting
-
Rambam Health Care CampusUnknownMultiple Sclerosis
-
InSightecRecruitingTremor Associated With Tremor Dominant Parkinson's DiseaseUnited States